

SynAct Pharma to participate at ABGSC Life Science Summit May 30

SynAct Pharma AB (publ) ("SynAct") today announced that the company is participating at ABG Sundal Collier's Life Science Summit on May 30 at 10:30 CEST, where CEO Torbjørn Bjerke will present and answer questions about the latest development in the company.

The conference will take place at ABG Sundal Collier at Regeringsgatan 25 in Stockholm. The presentation will be put on SynAct's website after the event.

The information was submitted, through the agency of the contact person below, for publication on May 29, 2023, at 08:00 a.m CEST.

For further information, please contact:

Torbjørn Bjerke, MD

CEO, SynAct Pharma AB

Phone: +46 727 44 41 58

Mail: TBJE@synactpharma.com

Mail: investor.relations@synactpharma.com

About SynAct Pharma AB

SynAct Pharma AB (publ) (Nasdaq Stockholm: SYNACT) conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates aimed at acute deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms.

For more information, please visit the company's web page: www.synactpharma.com.

Attachments

[SynAct Pharma to participate at ABGSC Life Science Summit May 30](#)